Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to $72.2 million.

  • Upstream Bio's Cash & Equivalents rose 11902.39% to $72.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.2 million, marking a year-over-year increase of 11902.39%. This contributed to the annual value of $325.9 million for FY2024, which is 116153.37% up from last year.
  • Latest data reveals that Upstream Bio reported Cash & Equivalents of $72.2 million as of Q3 2025, which was up 11902.39% from $45.5 million recorded in Q2 2025.
  • In the past 5 years, Upstream Bio's Cash & Equivalents registered a high of $325.9 million during Q4 2024, and its lowest value of $25.8 million during Q4 2023.
  • Its 3-year average for Cash & Equivalents is $77.8 million, with a median of $47.3 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Upstream Bio's Cash & Equivalents was 116153.37% (2024), while the steepest drop was 3036.9% (2024).
  • Over the past 3 years, Upstream Bio's Cash & Equivalents (Quarter) stood at $25.8 million in 2023, then soared by 1161.53% to $325.9 million in 2024, then plummeted by 77.86% to $72.2 million in 2025.
  • Its last three reported values are $72.2 million in Q3 2025, $45.5 million for Q2 2025, and $71.3 million during Q1 2025.